Eliem Therapeutics Inc. (ELYM)
5.11
-0.05 (-0.97%)
At close: Oct 02, 2024, 8:00 PM
5.11
0.00%
After-hours: Oct 02, 2024, 07:46 PM EDT
-0.97% (1D)
| Bid | 4.95 |
| Market Cap | 342.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.19M |
| EPS (ttm) | -2.22 |
| PE Ratio (ttm) | -2.3018018018018016 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 5.3 |
| Volume | 802,692 |
| Avg. Volume (20D) | 519,722 |
| Open | 5.12 |
| Previous Close | 5.16 |
| Day's Range | 5.00 - 5.26 |
| 52-Week Range | 2.35 - 11.55 |
| Beta | -0.38 |
About ELYM
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 10, 2021
Employees 9
Stock Exchange NASDAQ
Ticker Symbol ELYM
Website https://www.eliemtx.com
8 months ago
-3.38%
Eliem Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription